Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Are grade III / IV toxicities the only ones that matter?

How does EMA look at toxicity/benefit ratios in cancer treatment

Date

11 Sep 2017

Session

Are grade III / IV toxicities the only ones that matter?

Topics

Supportive Care and Symptom Management;  Bioethical Principles and GCP;  Therapy

Presenters

Francesco Pignatti

Authors

F. Pignatti

Author affiliations

  • Scientific And Regulatory Management , European Medicines Agency (EMA), E14 4HB - London/GB
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.